Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer

Uterine cervix cancers pose therapeutic challenges because of an overactive ribonucleotide reductase, which provides on-demand deoxyribonucleotides for DNA replication or for a DNA damage repair response. Ribonucleotide reductase overactivity bestows cancer cell resistance to the effects of radiothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunos, Charles A., Capala, Jacek, Kohn, Elise C., Ivy, Susan Percy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607970/
https://www.ncbi.nlm.nih.gov/pubmed/31297338
http://dx.doi.org/10.3389/fonc.2019.00560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607970/
https://www.ncbi.nlm.nih.gov/pubmed/31297338
http://dx.doi.org/10.3389/fonc.2019.00560

Ejemplares similares